C-terminal HSP90 inhibitors
Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
1 . A pharmaceutical composition comprising: a compound of the formula:
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
2 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical acceptable carrier is a solid filler or excipient.
3 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a solid.
4 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.
5 . The pharmaceutical composition of claim 1 , wherein the compound is present in the pharmaceutical composition in a therapeutically effective amount.
6 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a compound of the formula:
7 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as a tablet.
8 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as a capsule.
9 . A method of treating or preventing a neurodegenerative disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition of claim 1 .
10 . The method of claim 9 , wherein the neurodegenerative disorder is sensory neuron glucotoxicity.
11 . The method of claim 10 , wherein the sensory neuron glucotoxicity results from hyperglycemia.
12 . The method of claim 11 , wherein the hyperglycemia is associated with a diabetic condition.
13 . The method of claim 10 , wherein the sensory neuron glucotoxicity results in diabetic peripheral neuropathy.
14 . The method of claim 9 , wherein the method comprises treating the neurodegenerative disorder.
15 . The method of claim 14 , wherein the method comprises delaying or slowing the progression of the neurodegenerative disorder.
16 . The method of claim 14 , wherein the method ameliorates one or more symptoms of the neurodegenerative disorder.
17 . The method of claim 9 , wherein the method comprises preventing the neurodegenerative disorder.
18 . The method of claim 17 , wherein the method comprises delaying the onset of the neurodegenerative disorder.
19 . The method of claim 9 , wherein the therapeutically effective amount is an amount sufficient to inhibit the progression of the disorder.
20 . The method of claim 16 , wherein the symptom of the neurodegenerative disorder is pain.